Peking University People's Hospital: Myelodysplastic Syndromes trials

The registry lists 13 Myelodysplastic Syndromes studies with Peking University People's Hospital as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 8No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNINot yet recruitingNCT07796620Phase 1/2
• Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCTRecruitingNCT07677306Phase 2
• IFN-α in Relapse Prevention.Not yet recruitingNCT07449286Phase 2
• Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCTNot yet recruitingNCT07319793Not applicable
• Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCTRecruitingNCT06984536Phase 2
• Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow CytometryRecruitingNCT06569095
• Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin InhibitorsNot yet recruitingNCT06279494Phase 1/2
• Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCTRecruitingNCT06130579Phase 2
• Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic SyndromeRecruitingNCT05902416
• RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCTRecruitingNCT03412409Phase 2
• RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCTStatus unknownNCT03412266Phase 2
• Study of New RIC Regimen of BuFlu in Older and/or Intolerable PatientsStatus unknownNCT01828619
• Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic SyndromeCompletedNCT01793675